Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of Abaloparatide in Spinal Fusion Surgery (FAST-Healing)
NCT03841058Phase 2Active, not recruiting
- Sponsor
- Hospital for Special Surgery
- Start
- Aug 2019
- Primary completion
- Feb 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of abaloparatide in spinal fusion (3 arms), sponsored by Hospital for Special Surgery. Primary endpoints: Difference in measure of fusion mass bridging from transverse process to transverse process at 1 year and Difference in incidence of adverse surgical outcomes at 1 year. Started Aug 2019; status: active, not recruiting.
02
Drugs
abaloparatide
03
Conditions
spinal fusion
Beyond the preview
Go deeper on NCT03841058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03841058.